Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Mantle Cell Lymphoma

ABSTRACT: Gene expression analyis of primary MCL including IGHV mutated and unmutated cases Gene set analysis was perfomed in MCL samples, comparing IGHV mutated cases vs. IGHV unmutated cases In total 38 MCL samples were processed with the HU133plus 2.0 microarray. Twenty four cases had a IGHV mutations and 14 were unmutated.

ORGANISM(S): Homo sapiens

SUBMITTER: Pedro Jares

PROVIDER: E-GEOD-36000 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Navarro Alba A Clot Guillem G Royo Cristina C Jares Pedro P Hadzidimitriou Anastasia A Agathangelidis Andreas A Bikos Vasilis V Darzentas Nikos N Papadaki Theodora T Salaverria Itziar I Pinyol Magda M Puig Xavier X Palomero Jara J Vegliante Maria Carmela MC Amador Virgina V Martinez-Trillos Alejandra A Stefancikova Lenka L Wiestner Adrian A Wilson Wyndham W Pott Christiane C Calasanz Maria Jose MJ Trim Nicola N Erber Wendy W Sander Birgitta B Ott German G Rosenwald Andreas A Colomer Dolors D Giné Eva E Siebert Reiner R Lopez-Guillermo Armando A Stamatopoulos Kostas K Beà Sílvia S Campo Elías E

Cancer research 20120820 20

Mantle cell lymphoma (MCL) is a heterogeneous disease with most patients following an aggressive clinical course, whereas others having an indolent behavior. We conducted an integrative and multidisciplinary analysis of 177 MCL to determine whether the immunogenetic features of the clonotypic B-cell receptors (BcR) may identify different subsets of tumors. Truly unmutated (100% identity) IGHV genes were found in 24% cases, 40% were minimally/borderline mutated (99.9%-97%), 19% significantly muta ...[more]

PMID: 22915760

Similar Datasets

Project description:Prospective series of 136 clinical monoclonal B lymphocytosis (cMBL) and 216 chronic lymphocytic leukemia (CLL) Rai 0 patients, were investigated in this study. While the distribution of CD38 and ZAP-70 positivity was similar, IGHV-mutated cases were more frequent among cMBL (P = 0.005). A Cox multivariate analysis on the whole patient cohort showed that cMBL condition was predictive of longer PFS, while CD38 expression and IGHV-unmutated status and CD38 expression correlated significantly with a shorter PFS in cMBL and Rai0-CLL, respectively. Trisomy 12, 11q- and 17p- abnormalities were scanty and of no predictive value in both conditions. Notably, gene and miRNA expression profiling showed no significant differences between cMBL and Rai0-CLL. Furthermore, similar gene and miRNA expression signatures were found in cMBL and Rai0-CLL according to the IGHV gene mutational status: that is, unmutated cases had different signatures from mutated cases, irrespectively of the cMBL or CLL condition. Overall, our study based on a prospective series of patients indicates that no major biological differences exist in cMBL compared to Rai0-CLL, suggesting that this two entities mainly differ for the initial size of the monoclonal cell population which may reflect in the longer time for clonal expansion. This series of microarray experiments contains the gene expression profiles of purified B-cell chronic lymphocytic leukemia (B-CLL) cells obtained from 160 patients (Binet stage A) including 45 cMBL and 115 Rai0-CLL. Peripheral blood mononuclear cells from CLL patients were isolated by Ficoll-Hypaque (Seromed, Biochrom KG, Berlin, Germany) density-gradient centrifugation. For gene and miRNA expression profiling experiments CLL cells were enriched by negative selection with the EasySep-Human B cell enrichment kit without CD43 depletion (Stem Cell Technologies) using the fully automated protocol of immunomagnetic cell separation with RoboSepTM (Stem Cell Technologies).

Dataset Information

Mantle Cell Lymphoma

Publications

Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure